Physician
Mcfayden Eyo & Strottand Assoc PA
Mcfayden Eyo & Strottand Assoc PA was paid $3.27M by Medicaid between Jan 2018 and Dec 2024, across 64 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 40% of everything it billed.
33Billing provider infoMCFAYDEN EYO & STROTTAND ASSOC PA
SALISBURY, MD 21801
SALISBURY, MD 21801
33aNPI1356377691assigned 06/25/2006
33bProvider typePediatrics Physician
28Total paid$3.27M
24GClaims141,911
24DCodes billed64
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Maryland
Rank by total paid#35 of 306
Median peer was paid$206K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 368 | $9K | |
| 2019 | 448 | $11K | |
| 2020 | 15,839 | $488K | |
| 2021 | 23,653 | $677K | |
| 2022 | 36,284 | $794K | |
| 2023 | 31,181 | $659K | |
| 2024incomplete | 34,138 | $634K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 40% | 14,883 | 9,129 | $1.32M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 10,490 | 6,934 | $682K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.2% | 2,188 | 1,582 | $169K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.1% | 2,051 | 1,552 | $168K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.9% | 1,711 | 1,107 | $128K |
| 99401 | 3.6% | 5,805 | 2,706 | $117K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.4% | 1,688 | 1,030 | $111K |
| 92552 | 2.9% | 5,589 | 3,875 | $96K | |
| D1206 | Topical application of fluoride varnish | 2.1% | 2,726 | 2,677 | $68K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.5% | 519 | 242 | $49K |
| 90686 | 1.2% | 2,352 | 1,700 | $39K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.2% | 5,786 | 3,736 | $38K |
52 more codes
| 94010 | <1% | 1,386 | $27K | |
| 96127 | <1% | 10,854 | $25K | |
| 96160 | <1% | 16,822 | $23K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 2,270 | $20K |
| 3074F | <1% | 3,044 | $17K | |
| 3078F | <1% | 3,043 | $17K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 986 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,732 | $14K |
| 90648 | <1% | 956 | $14K | |
| 99173 | <1% | 5,804 | $10K | |
| 94760 | <1% | 9,924 | $10K | |
| 90670 | <1% | 573 | $9K | |
| 92567 | <1% | 641 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,393 | $9K |
| 81002 | <1% | 3,854 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 321 | $7K |
| 96161 | <1% | 4,113 | $7K | |
| 90723 | <1% | 531 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 307 | $5K |
| 94664 | <1% | 650 | $5K | |
| 90680 | <1% | 459 | $5K | |
| 90677 | <1% | 387 | $5K | |
| 90656 | <1% | 283 | $4K | |
| A7005 | Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable | <1% | 323 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 62 | $3K |
| 99051 | <1% | 402 | $3K | |
| 99070 | <1% | 1,066 | $2K | |
| 90480 | <1% | 86 | $1K | |
| 0072A | <1% | 33 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 500 | $1K |
| 90734 | <1% | 45 | $814.80 | |
| 0071A | <1% | 16 | $642.06 | |
| 90651 | <1% | 29 | $605.27 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 322 | $582.32 |
| 90620 | <1% | 33 | $582.00 | |
| 0003A | <1% | 13 | $520.00 | |
| 0001A | <1% | 22 | $520.00 | |
| 90633 | <1% | 37 | $279.36 | |
| 0124A | <1% | 29 | $240.00 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 69 | $70.98 |
| 99000 | <1% | 4,288 | $46.09 | |
| 99072 | <1% | 1,171 | $26.28 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 319 | $17.73 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 211 | $14.72 |
| G9920 | Screening performed and negative | 0% | 600 | $0.00 |
| 91312 | 0% | 29 | $0.00 | |
| 91300 | 0% | 89 | $0.00 | |
| 90661 | 0% | 345 | $0.00 | |
| G9521 | Total number of emergency department visits and inpatient hospitalizations less than two in the past 12 months | 0% | 979 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 2,516 | $0.00 |
| G9432 | Asthma well-controlled based on the act, c-act, acq, or ataq score and results documented | 0% | 978 | $0.00 |
| 91307 | 0% | 178 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCFAYDEN EYO, SHARON (SECRETARY TREASURER)